391P Phase II results of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with pancreatic and biliary tract cancer
Year: 2024
Type: article
Study design: Clinical Trial
Source: Annals of Oncology
Authors: J.A. Bridgewater, L. Chantrill, R. Gillmore, R. Hubner, N. Starling, F. Froeling, H.S. Wasan, B. Basu, F. Collison, B. Markman, M. Chisamore, L. Goodwin, D. Wilson, C. Phillips, J. Robertson, H. Timmis, Z. Setchellova, S.A. Woodcock, J.W. Valle
Institutions: University College London, Royal Free London NHS Foundation Trust, The Royal Free Hospital, University of Manchester, The Christie NHS Foundation Trust, Royal Marsden NHS Foundation Trust, Beatson West of Scotland Cancer Centre, Imperial College Healthcare NHS Trust, University of Cambridge, University of Leeds, The Alfred Hospital, Alfred Health, Monash University, Merck & Co., Inc., Rahway, NJ, USA (United States), Redx Pharma (United Kingdom), Cholangiocarcinoma Foundation
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4400151304